Home > News > Champions Licenses IND-Poised Liposomal Irinotecan as Lead Candidate
April 1st, 2011
Champions Licenses IND-Poised Liposomal Irinotecan as Lead Candidate
Abstract:
Champions Biotechnology exercised its option to license a late preclinical-stage liposomal nanoparticle formulation of irinotecan known as Irinophore C™ from Canada's BC Cancer Agency, part of British Columbia's Provincial Health Services Authority. The Baltimore-based firm will pay BC Cancer $85,000 to cover the option exercise fee and past patent costs incurred by BC Cancer. It has in addition decided to drop development of another three previously in-licensed candidates and will not pursue any other product in-licensing opportunities.
Source:
genengnews.com
Related News Press |
News and information
FSU researchers develop new methods to generate and improve magnetism of 2D materials December 13th, 2024
Innovative biomimetic superhydrophobic coating combines repair and buffering properties for superior anti-erosion December 13th, 2024
Groundbreaking research unveils unified theory for optical singularities in photonic microstructures December 13th, 2024
Nanomedicine
How cells repair DNA’s protective barrier: a pathway to address a rare genetic disorder characterized by rapid aging in children December 13th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
FSU researchers develop new methods to generate and improve magnetism of 2D materials December 13th, 2024
Innovative biomimetic superhydrophobic coating combines repair and buffering properties for superior anti-erosion December 13th, 2024
Groundbreaking research unveils unified theory for optical singularities in photonic microstructures December 13th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||